Related Experiment Video
Updated: Jul 3, 2026

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats
Published on: April 21, 2017
[Case of juvenile stroke caused by methylenetetrahydrofolate reductase deficiency]
Naoki Yuasa1, Tatsuya Ishikawa, Kentaro Tokuoka
1Department of Neurology, Tokai University Hachioji Hospital.
Abstract:
The patient had suffered from left hemiparesis at the age of thirteen months, and acute ischemic stroke of unknown etiology had been diagnosed at that time. His hemiparesis gradually disappeared and he was discharged two weeks after the onset without disability. At the age of 17 years, MRI following minor head trauma revealed cerebral infarctions located at the right corona radiata and basal ganglia. Laboratory findings showed hyperhomocysteinemia. Genetic study disclosed methylenetetrahydrofolate reductase deficiency (MTHFRD) (valine/valine type). MTHFRD is not detected by the routine infantile mass screening test for congenital amino acid metabolic disease, and should be considered in any patient with ischemic stroke at under two years of age.
Insights
Methylenetetrahydrofolate reductase deficiency (MTHFRD) can cause ischemic stroke in young children. This genetic condition, often missed by newborn screening, requires consideration in pediatric stroke cases.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Ischemic stroke in childhood is rare and often lacks a clear cause.
- Early diagnosis and management are crucial for preventing long-term neurological deficits.
Observation:
- A patient experienced hemiparesis at 13 months, diagnosed as acute ischemic stroke of unknown etiology.
- At 17 years, recurrent cerebral infarctions were detected after minor head trauma.
- Laboratory tests revealed hyperhomocysteinemia, a risk factor for stroke.
Findings:
- Genetic analysis identified methylenetetrahydrofolate reductase deficiency (MTHFRD), specifically the valine/valine genotype.
- MTHFRD is not typically detected through routine infantile screening for metabolic disorders.
Implications:
- MTHFRD should be considered in the differential diagnosis of ischemic stroke in patients, especially those under two years of age.
- This finding highlights the importance of comprehensive genetic testing in pediatric stroke evaluations.
- Early identification of MTHFRD can lead to targeted treatment and potentially prevent future cerebrovascular events.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Inborn Errors of Metabolism
Rocky Mountain Spotted Fever
Ischemic Stroke ll: Pathophysiology
Pedigree Analysis

